Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

PERAMPANEL EFFECTIVENESS IN THE TREATMENT OF REFRACTERY PARTIAL ONSET EPILEPSY WITH OR WITHOUT SECONDARY GENERALIZATION: PHARMACOECONOMIC ANALYSIS FOR THE RUSSIAN FEDERATION HEALTH CARE SYSTEM

https://doi.org/10.17749/2070-4909.2017.10.1.029-038

Full Text:

Abstract

Perampanel (PER) is a novel drug for treatment of refractory partial epilepsy in patients≥12 y.o. with proven efficacy and safety. PER is registered and may also be used successfully as adjunctive treatment in therapy of primary generalized tonic-clonic seizures (PGTCS).

Objective. To determine the effectiveness of perampanel and it`s clinical stability in patients at different dosing regimens, and evaluate the cost of treatment with perampanel in the Russian Health Care system.

Materials and Methods. Results of open multicenter controlled randomized (phase III) international clinical trials in patients over 12 years of age were used. Modeling of the direct costs was based on (i) the probable treatment outcomes: i.e., no clinical effect, treatment cessation due to adverse events, seizures reduction of 50% and more, complete seizure termination, (ii) the expected number of the above outcomes all overRussia, and (iii) the inflation risks in the period until 2020.

Results. The comparison of different clinical studies on adjunctive perampanel therapy in refractery partial epilepsy with or without secondary generalization as well as in primary generalized tonic-clonic seizures, reveales that the optimal daily dose of perampanel is 8 mg.

Conclusion. Direct costs modeling was performed to estimate annual expenses (per patient) of the adjunctive perampanel therapy. When recalculated for all patients with refractory partial epilepsy and for all patients with PGTCS inRussia, the results indicate that the introduction of perampanel may reduce the costs by more than 40% (up to 4-7 bln. rubles) annually until 2020. 

About the Authors

N. K. Mazina
Kirov State Medical Academy
Russian Federation

Mazina Nadezhda Konstantinovna – MD, head of the Department of pharmacology. 

Address: ul. K. Marksa, 112, Kirov, Russia, 610027



I. V. Sheshunov
Kirov State Medical Academy
Russian Federation

Sheshunov Igor’ Vyacheslavovich – MD, Professor, rector. 

Address: ul. K. Marksa, 112, Kirov, Russia, 610027



P. V. Мazin
Kirov State Medical Academy
Russian Federation

Mazin Pavel Vladimirovich – assistant to the rector, assistant Professor, Department of pharmacology. 

Address: ul. K. Marksa, 112, Kirov, Russia, 610027



Yu. V. Kislitsin
Kirov State Medical Academy
Russian Federation

Kislitsyn Yurii Vital’evich – MD, Professor, head of the Department of pharmacology. 

Address: ul. K. Marksa, 112, Kirov, Russia, 610027



E. M. Markova
Kirov State Medical Academy
Russian Federation

Markova Elena Mikhailovna – senior researcher of the Department of pharmacology. 

Address: ul. K. Marksa, 112, Kirov, Russia, 610027



References

1. Belousov Yu.B., Belousov D.Yu., Chikina E.S., Grigor’ev V.Yu., Mednikov I. I., Beketov A.S. Kachestvennaya meditsinskaya praktika. 2004; 4: 3-89.

2. Vlasov P.N. Nevrologiya, neiropsikhiatriya, psikhosomatika. 2016; (special issue 1): 4-10.

3. The health of Russia in 2015. Statistical book, Federal state statistics service (Rosstat). Ed. by M.A. Dianov [Zdravookhranenie Rossii v 2015 godu. Statisticheskii sbornik Federal’noi sluzhby gosudarstvennoi statistiki (Rosstat). Pod red. M.A. Dianova (in Russian)]. Moscow. 2015. www.gks.ru/free_doc/doc_2015/zdrav15.pdf. Data obrashcheniya: 09.01.2017.

4. Guekht A., Hauser W., Milchakova L., Churillin Y. et al. The epidemiology of epilepsy in Russian Federation. Epilepsy research. 2010; 92: 209-218.

5. Kolyagin V.V. Etiologiya, klassifikatsiya i lechenie epilepsii. Irkutsk: RIO IGIU VA: 2010. URL: http://www.docplayer.ru/28601202Etiologiya-klassifikacii-i-lechenie-epilepsii.html. Accessed: 09.01.2017.

6. Belousov D.Yu., Afanas’eva E.V., Efremova E.A. Farmakoekonomicheskii analiz primeneniya perampanela pri rezistentnoi partsial’noi epilepsii. Kachestvennaya klinicheskaya praktika. 2014; 1: 24-39.

7. Mkrtchyan V.R., Sergeev A.M., Pochigaeva K. I., Shpak I.A. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology. 2016: 9 (2): 28-37.

8. Pyadushkina E.A., Frolov M.Yu. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology. 2016; 9 (3): 38-47.

9. Burd S.G., Rubleva E.V., Serdyuk S.  E. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2015: 10 (115): 29-32.

10. French J., Krauss G., Biton V. et al. Adjunctive perampanel for refractory partial-onset seizures: Randomized phase III study 304. Neurology. 2012; 79: 589-596.

11. Krauss G., Serratosa J., Villanueva V. et al. Randomized phase III study 306. Adjunctive perampanel for refractory partial-onset seizures. Neurology. 2012; 78: 1408-1415.

12. Rogawski M., Hanada T. Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand. 2013: 127 (197): 19-24.

13. French J., Krauss G., Steinhoff B. et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: Results of randomized global phase III study 305. Epilepsia. 2013; 54 (1): 117-125. 1

14. Lagae L., Villanueva V., Meador K., et al. Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: A randomized study evaluating behavior, efficacy, and safety. Epilepsia. 2016; 57 (7): 1120-1129.

15. Steinhoff B., Hamer H., Trinka E. et al. A multicenter survey of clinical experiences with perampanel in real life in Germany and Austria. Epilepsy Research. 2014; 108: 986-988.

16. Karlov V.A., Belyaev O.V., Vlasov P.N., Zhidkova I.A i dr. Nevrologiya, neiropsikhiatriya, psikhosomatika. 2016; (special issue 1): 11-17.

17. The Website «Farmindeks.rf». www.pharmindex.ru. Accessed: 29.12.2016.

18. The website of the Federal service of state statistics (Rosstat). www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/population/demography. Accessed: 29.12.2016.

19. The Website «Agentstvo prognozirovaniya ekonomiki». www.apecon.ru/Prognoz-inflatsii-v-Rossii. Accessed: 29.12.2016.

20. The Website «Statbyuro». www.statbureau.org/ru/russia/inflation-calculators. Accessed: 10.01.2017.

21. French J.A., Krauss G. L., Wechsler R. T., Wang X. F. et al. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy. Neurology. 2015; 85 (11): 950-7.

22. The course of economic theory. Edited by MN Chepurina, EA Kiseleva [Kurs ekonomicheskoi teorii. Pod red. M.N. Chepurinoi, E.A. Kiselevoi (in Russian)]. Kirov. 2004.

23. Yagudina R. I., Kulikov A. Yu., Serpik V.G. Pharmacoeconomics [Farmakoekonomika (in Russian)]. Rostov n/D. 2017; 237.

24. Liu J., Yu N., Sun H., Liang Y., Xie Y., Chen K. Intermittent levetiracetam treatment in five patients with catamenial epilepsy. J Pak Med Assoc. 2015 Jul; 65 (7): 793-5.

25. Van Matre E.T., Cook A.M. Steady-state pharmacokinetic simulation of intermittent vs. continuous infusion valproic acid therapy in non-critically ill and critically ill patients. Neurol Res. 2016 Sep; 38 (9): 786-91. DOI:10.1080/01616412.2016.1206164. Epub 2016 Jul 14.


For citation:


Mazina N.K., Sheshunov I.V., Мazin P.V., Kislitsin Y.V., Markova E.M. PERAMPANEL EFFECTIVENESS IN THE TREATMENT OF REFRACTERY PARTIAL ONSET EPILEPSY WITH OR WITHOUT SECONDARY GENERALIZATION: PHARMACOECONOMIC ANALYSIS FOR THE RUSSIAN FEDERATION HEALTH CARE SYSTEM. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2017;10(1):29-38. (In Russ.) https://doi.org/10.17749/2070-4909.2017.10.1.029-038

Views: 426


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)